Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
COMPLETED
NCT05278962
PHASE4
HF Patients With LVADs Being Treated With SGLT2i
Sponsor: University of Chicago
View on ClinicalTrials.gov
Summary
The main purpose of this study is to observe outcomes of sodium-glucose co-transporter 2 inhibitors (SGLT2i) in heart failure (HF) patients with left ventricular assist devices (LVAD).
Official title: Heart Failure Patients With Left Ventricular Assist Devices Being Treated With Sodium-Glucose Co-Transporter 2 Inhibitors
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
32
Start Date
2022-09-08
Completion Date
2025-08-31
Last Updated
2026-06-03
Healthy Volunteers
No
Interventions
DRUG
SGLT2i
empagliflozin (10 mg daily) or dapagliflozin (10 mg daily), depending on formulary coverage
OTHER
No SGLT2i
No SGLT2i
Locations (1)
University of Chicago
Chicago, Illinois, United States